CR10012A - Formulaciones de proteina de fusión de Inmunoglobulina - Google Patents
Formulaciones de proteina de fusión de InmunoglobulinaInfo
- Publication number
- CR10012A CR10012A CR10012A CR10012A CR10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fusion protein
- compositions
- immunoglobulin fusion
- protein formulations
- disaccharide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a composiciones de proteínas de fusión de Ig, especialmente composiciones que incluyen una proteína de fusión de Ig, un agente de volumen, un disacárido, un tensioactivo, y un amortiguador. En un aspecto, estas composiciones son estables bajo almacenamiento a largo plazo o al menos un ciclo de congelación/descongelación. La invención también proporciona métodos de preparación de las composiciones de proteína de fusión de Ig. En un aspecto, adicional, las composiciones son liofilizadas por un proceso que incluye una etapa de recocido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73927105P | 2005-11-22 | 2005-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10012A true CR10012A (es) | 2008-07-29 |
Family
ID=37781927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10012A CR10012A (es) | 2005-11-22 | 2008-05-22 | Formulaciones de proteina de fusión de Inmunoglobulina |
Country Status (14)
Country | Link |
---|---|
US (2) | US20070237758A1 (es) |
EP (1) | EP1951305A1 (es) |
JP (1) | JP2009516692A (es) |
KR (1) | KR20080071192A (es) |
CN (1) | CN101312744A (es) |
AU (1) | AU2006318583A1 (es) |
BR (1) | BRPI0618893A2 (es) |
CA (1) | CA2630115A1 (es) |
CR (1) | CR10012A (es) |
EC (1) | ECSP088459A (es) |
NO (1) | NO20082133L (es) |
RU (1) | RU2008118166A (es) |
SV (1) | SV2009002911A (es) |
WO (1) | WO2007062040A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2377554A1 (en) * | 2005-07-22 | 2011-10-19 | Amgen, Inc | Concentrated protein lyophilates, methods and uses |
JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗il−13抗体製剤およびその使用 |
US20080200656A1 (en) * | 2007-02-16 | 2008-08-21 | Wyeth | Use Of Sucrose To Suppress Mannitol-Induced Protein Aggregation |
JP5469077B2 (ja) * | 2007-11-12 | 2014-04-09 | アレス トレーディング ソシエテ アノニム | Taci−免疫グロブリン融合タンパク質のための調製物 |
UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
JP2012530721A (ja) * | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
CN101693016B (zh) * | 2009-11-02 | 2012-07-25 | 北京美福源生物医药科技有限公司 | 通用的注射用重组人血清白蛋白融合蛋白制剂配方 |
ES2679819T3 (es) | 2009-11-03 | 2018-08-31 | Grifols Therapeutics Inc. | Composición, método y kit para inhibidor de alfa-1 proteinasa |
AU2010324839B2 (en) | 2009-11-24 | 2015-02-19 | Grifols Therapeutics Inc. | Lyophilization methods, compositions, and kits |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
WO2012101251A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Human antibodies to pcsk9 for use in methods of treatment based on particular dosage regimens |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
CN104940926B (zh) | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN105435222B (zh) * | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
GB201513010D0 (en) | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
CA3099551A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
WO2020021330A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
CN110607553B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种制备粒径可调的药物或药物中间体单晶或无定型物的方法 |
CN111195349B (zh) * | 2018-11-16 | 2023-02-24 | 鲁南制药集团股份有限公司 | 一种代谢调节融合蛋白的冻干粉制剂 |
MX2021008017A (es) * | 2019-01-06 | 2021-08-05 | Endo Global Aesthetics Ltd | Formulaciones de colagenasa y metodos de produccion de las mismas. |
CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
CN113474360A (zh) | 2019-02-18 | 2021-10-01 | 伊莱利利公司 | 治疗性抗体制剂 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
SI2275119T1 (sl) * | 1995-07-27 | 2013-12-31 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
JP3900664B2 (ja) * | 1997-09-26 | 2007-04-04 | 株式会社ニコン | 顕微鏡 |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
DK2130554T3 (da) * | 1999-02-22 | 2012-12-03 | Univ Connecticut | Albuminfrie faktor VIII-præparater |
AU4314900A (en) * | 1999-04-28 | 2000-11-17 | Yamanouchi Pharmaceutical Co., Ltd. | Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same |
ATE402716T1 (de) * | 2002-02-27 | 2008-08-15 | Immunex Corp | Stabilisierte tnfr-fc formulierung mit arginin |
US20050226893A1 (en) * | 2004-03-04 | 2005-10-13 | Jennifer Juneau | Lyophilization method to improve excipient crystallization |
-
2006
- 2006-11-21 JP JP2008541422A patent/JP2009516692A/ja not_active Withdrawn
- 2006-11-21 WO PCT/US2006/045059 patent/WO2007062040A1/en active Application Filing
- 2006-11-21 RU RU2008118166/15A patent/RU2008118166A/ru not_active Application Discontinuation
- 2006-11-21 KR KR1020087015109A patent/KR20080071192A/ko not_active Application Discontinuation
- 2006-11-21 BR BRPI0618893-1A patent/BRPI0618893A2/pt not_active IP Right Cessation
- 2006-11-21 US US11/562,299 patent/US20070237758A1/en not_active Abandoned
- 2006-11-21 EP EP06838185A patent/EP1951305A1/en not_active Withdrawn
- 2006-11-21 CN CNA2006800437873A patent/CN101312744A/zh active Pending
- 2006-11-21 CA CA002630115A patent/CA2630115A1/en not_active Abandoned
- 2006-11-21 AU AU2006318583A patent/AU2006318583A1/en not_active Abandoned
-
2008
- 2008-05-07 NO NO20082133A patent/NO20082133L/no not_active Application Discontinuation
- 2008-05-19 EC EC2008008459A patent/ECSP088459A/es unknown
- 2008-05-22 SV SV2008002911A patent/SV2009002911A/es unknown
- 2008-05-22 CR CR10012A patent/CR10012A/es not_active Application Discontinuation
-
2010
- 2010-10-22 US US12/910,146 patent/US20110033464A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101312744A (zh) | 2008-11-26 |
CA2630115A1 (en) | 2007-05-31 |
RU2008118166A (ru) | 2009-12-27 |
JP2009516692A (ja) | 2009-04-23 |
US20110033464A1 (en) | 2011-02-10 |
EP1951305A1 (en) | 2008-08-06 |
US20070237758A1 (en) | 2007-10-11 |
KR20080071192A (ko) | 2008-08-01 |
BRPI0618893A2 (pt) | 2011-09-13 |
WO2007062040A1 (en) | 2007-05-31 |
NO20082133L (no) | 2008-06-16 |
AU2006318583A1 (en) | 2007-05-31 |
SV2009002911A (es) | 2009-03-04 |
ECSP088459A (es) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10012A (es) | Formulaciones de proteina de fusión de Inmunoglobulina | |
BRPI0608342A2 (pt) | antìgenos recombinantes quiméricos de toxoplasma gondii | |
TN2012000023A1 (en) | Subcutaneous anti-her2 antibody formulation | |
AR072058A1 (es) | Composicion detergente que comprende una variante de la familia 44 de xiloglucanasas | |
CY1116285T1 (el) | Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα | |
MX2007010771A (es) | Anfifilos peptidicos para union a heparina angiogenicos. | |
SG144075A1 (en) | Protein stabilization formulations | |
PE20090738A1 (es) | Formulaciones de anticuerpos | |
DE60135498D1 (de) | Produktion von ganzen Antikörpern in prokaryontischen Zellen | |
MX2012006831A (es) | Formacion de anticuerpos. | |
CL2007001185A1 (es) | Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis | |
AR037971A1 (es) | Preparacion liofilizada que contiene un anticuerpo contra el receptor egf | |
ECSP077246A (es) | Formulaciones Estabilizadoras | |
TW200700092A (en) | Tigecycline compositions and methods of preparation | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
NO20062044L (no) | Piscirickettsia salmonis-antigener og anvendelse derav | |
AR052339A1 (es) | Formulaciones terapeuticas del factor de crecimiento queratinocitico | |
CY1114310T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου | |
BRPI0613362A8 (pt) | polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção | |
EA201100071A1 (ru) | Новые композиции и способы | |
MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
DK1276763T3 (da) | Anti-fryseproteiner, deres fremstilling og anvendelse | |
WO2006079722A3 (fr) | Compositions pour la lyophilisation de proteines | |
MY140244A (en) | Surfactant system | |
MX2021011530A (es) | Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |